RT Journal Article
SR Electronic
T1 Comparison of global uptake of NaF-PET/CT in whole-body bone in multiple myeloma and healthy controls.
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 768
OP 768
VO 58
IS supplement 1
A1 Zirakchian Zadeh, Mahdi
A1 Oestergaard, Brian
A1 Raynor, William
A1 Taghvaei, Raheleh
A1 Acosta-Montenegro, Oswaldo
A1 Ayubcha, Cyrus
A1 Khosravi, Mohsen
A1 Constantinescu, Caius
A1 Nielsen, Anne
A1 Werner, Thomas
A1 Abildgaard, Niels
A1 Hoilund-Carlsen, Poul Flemming
A1 Alavi, Abass
YR 2017
UL http://jnm.snmjournals.org/content/58/supplement_1/768.abstract
AB 768Objectives: The aim of this study was to compare the global NaF uptake of the skeleton in MM patients and healthy control subjects.Methods: 16 patients with MM (range: 55-76 years, mean age 64) and 16 healthy control subjects (range: 50-75 years, mean age: 62) were included in this research study. Controls were matched to patients by sex and age (±5 years). All subjects underwent NaF-PET/CT scanning 90 minutes following administration of NaF. All MM patients had more than two lesions in their entire skeleton. NaF-PET data of the patients were collected before initiation of treatment and 2 months later (NCT02187731). Global assessment of overall skeleton activity was obtained by fusing the PET and the CT and then applying a threshold algorithm based on bone Hounsfield scale from the CT scan, enabling the segmentation and quantification of NaF uptake in the entire skeleton (OsiriX software; Pixmeo SARL; Bernex, Switzerland). The mean standard uptake value (SUVmean) of the control group was compared to that of the patients pre- and post-treatment.Results: The global skeletal SUVmean of patients before treatment was significantly higher than that of the control group (3.58 and 2.89 respectively, P =0.047). However, the difference found between the SUVmean of patients after treatment and the control group was statically insignificant (3.00 and 2.89 respectively).Conclusion: The significant difference between the global SUVmean of MM patients before treatment and control subjects may be related to bone lesions and insufficiency fractures in the ribs, spine, and pelvis in these patients. The lack of significant difference in NaF uptake in the patients after treatment compared to controls could be related to decreasing number of myeloma lesions and possibly decreasing incidence of insufficiency fractures after the treatment. Further studies involving larger sample sizes are needed to confirm our findings.